News
Latest News | Chronos Therapeutics
Positive pre-clinical proof of concept in MS fatigue model
Chronos announces positive pre-clinical results for the lead compound in its DAT inhibitor programme in an in vivo model of fatigue in multiple sclerosis (MS). Read the press release.
Positive pre-clinical proof of concept studies in orexin-1 antagonist project
Chronos has demonstrated positive pre-clinical proof of concept (POC) results for the lead compound in its orexin-1 antagonist programme in an in vivo model of binge eating disorder (BED). Read the press release.
Second patent filed for novel orexin 1 antagonist programme
A second patent application for novel orexin 1 antagonists has been filed on 25 October 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol use disorder programmes.
Chronos Senior Mangement interviewed at The Telegraph studios
Chronos CEO, CSO and VP Corporate Development were interviewed at The Telegraph studios recently. Click here to see the interview on our approach to degenerative and behavioural brain disease.
Patent filed for novel orexin 1 antagonist programme
A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol use disorder programmes.